MURA (Mural Oncology) Institutional Ownership : 55.32% (As of Apr. 23, 2025)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mural Oncology's institutional ownership is 55.32%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mural Oncology's Insider Ownership is 3.40%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mural Oncology's Float Percentage Of Total Shares Outstanding is 99.99%.

Mural Oncology Institutional Ownership Historical Data

The historical data trend for Mural Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Institutional Ownership Chart

Mural Oncology Historical Data

The historical data trend for Mural Oncology can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Institutional Ownership	17.82	13.96	13.89	10.35	10.28	10.05	9.98	9.91	9.83	9.81

Mural Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Mural Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.muraloncology.com

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.